BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29573781)

  • 1. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
    Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
    Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
    Won HS; Jung CK; Chun SH; Kang JH; Kim YS; Sun DI; Kim MS
    Oral Oncol; 2012 Oct; 48(10):985-990. PubMed ID: 22682934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
    PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT/mTOR pathway and autophagy regulator genes in paranasal squamous cell carcinoma metastasis.
    Biray Avci C; Sezgin B; Goker Bagca B; Karci HB; Gode S
    Mol Biol Rep; 2020 May; 47(5):3641-3651. PubMed ID: 32319010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
    Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
    Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K-AKT-mTOR pathway proteins are differently expressed in oral carcinogenesis.
    Martins F; de Sousa SC; Dos Santos E; Woo SB; Gallottini M
    J Oral Pathol Med; 2016 Nov; 45(10):746-752. PubMed ID: 26991907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
    García-Carracedo D; Villaronga MÁ; Álvarez-Teijeiro S; Hermida-Prado F; Santamaría I; Allonca E; Suárez-Fernández L; Gonzalez MV; Balbín M; Astudillo A; Martínez-Camblor P; Su GH; Rodrigo JP; García-Pedrero JM
    Oncotarget; 2016 May; 7(20):29780-93. PubMed ID: 27119232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
    Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.
    Zhou L; Huang Y; Li J; Wang Z
    Med Oncol; 2010 Jun; 27(2):255-61. PubMed ID: 19301157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
    Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
    Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.
    Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X
    Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
    Shin E; Choi CM; Kim HR; Jang SJ; Park YS
    Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
    Yang J; Liao D; Wang Z; Liu F; Wu G
    J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.
    Azizi M; Tang DH; Verduzco D; Peyton CC; Chipollini J; Yuan Z; Schaible BJ; Zhou JM; Johnstone PA; Giuliano A; Dhillon J; Spiess PE
    Clin Genitourin Cancer; 2019 Feb; 17(1):e80-e91. PubMed ID: 30318447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.